<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093755</url>
  </required_header>
  <id_info>
    <org_study_id>09-007252</org_study_id>
    <nct_id>NCT01093755</nct_id>
  </id_info>
  <brief_title>Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?</brief_title>
  <official_title>Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that intensive acid suppression with a long acting high potency
      proton pump inhibitor (PPI) drug dexlansoprazole will lead to a greater decrease in levels of
      inflammatory mediators (compared to conventional PPIs) in the esophagus, which could
      potentially lead to decreased recurrence of intestinal metaplasia following endoscopic
      ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who achieve complete remission of intestinal metaplasia following ablation will be
      randomized (using concealed allocation, like the flip of a coin) to either intensive acid
      suppression with dexlansoprazole 60-90 mg/day or to symptom guided acid suppression with
      escalating doses of omeprazole (20-60 mg/day) for 6 months. Control of reflux will be
      assessed using 24 hour ambulatory pH monitoring. The need to escalate drug dosage at the 3
      month visit will be determined by presence of excessive acid exposure on ambulatory pH
      monitoring. Biopsies of esophageal tissue will be obtained at baseline, then at 3 months and
      6 months following randomization to measure changes in inflammatory biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Inflammation Biomarker Tissue PGE2 Level</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Change from baseline in esophageal tissue biopsy prostaglandin E2 (PGE2) level, as determined by enzyme immunoassay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Esophageal Inflammation Biomarker COX-2 Gene Expression</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Change from baseline in esophageal issue biopsy cyclooxygenase-2 (COX-2) gene expression, as determined by Western blot.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Inflammation</condition>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>dexlansoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexlansoprazole</intervention_name>
    <description>Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months</description>
    <arm_group_label>dexlansoprazole</arm_group_label>
    <other_name>Dexilant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Escalating doses of omeprazole (20-60 mg/day) for 6 months</description>
    <arm_group_label>omeprazole</arm_group_label>
    <other_name>Prilosec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients who have undergone ablation for Barrett's Esophagus (BE) and High Grade Dysplasia
        (HGD) or Low Grade Dysplasia (LGD) with Photodynamic Therapy (PDT)/Radiofrequency ablation
        and endoscopic mucosal resection who have no endoscopic and histologic evidence of
        specialized intestinal metaplasia on biopsies from the esophagus on two successive
        endoscopies post ablation will be offered enrollment in the study.

        Inclusion criteria:

          1. Absence of intestinal metaplasia on endoscopy (under Narrow Band Imaging) and on
             histology (from biopsies taken from gastroesophageal junction and distal esophagus) on
             two successive surveillance endoscopies.

          2. Able to consent to study

          3. Males and females age 18-90

          4. Life expectancy of 5 years or greater.

        Exclusion criteria:

          1. Pregnancy

          2. Inability to consent for the procedure

          3. Anticoagulation therapy precluding performance of ambulatory pH monitoring and/or
             biopsies

          4. Intolerance to proton pump inhibitors

          5. Elevation in Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), (liver
             enzymes), bilirubin or alkaline phosphatase more than five times the upper limit of
             normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prasad Iyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <results_first_submitted>February 19, 2016</results_first_submitted>
  <results_first_submitted_qc>February 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2016</results_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Prasad G. Iyer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Barrett's Esophagus</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Patients post-radiofrequency ablation for Barrett's Esophagus.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from Mayo Clinic patients in Rochester, Minnesota who had undergone an ablation procedure for Barrett's Esophagus.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexlansoprazole</title>
          <description>Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
dexlansoprazole: Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Omeprazole</title>
          <description>Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
Omeprazole: Escalating doses of omeprazole (20-60 mg/day) for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexlansoprazole</title>
          <description>Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
dexlansoprazole: Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Omeprazole</title>
          <description>Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
Omeprazole: Escalating doses of omeprazole (20-60 mg/day) for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="6.9"/>
                    <measurement group_id="B2" value="59.1" spread="8.9"/>
                    <measurement group_id="B3" value="61.5" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Grade Dysplasia/Intramucosal Carcinoma</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Subjects with High-Grade Dysplasia/Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Low-Grade Dysplasia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/height in meters^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="3.4"/>
                    <measurement group_id="B2" value="29.3" spread="4.2"/>
                    <measurement group_id="B3" value="30.14" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Barrett's Esophagus segment length, pre-ablation</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="3.5"/>
                    <measurement group_id="B2" value="4.8" spread="4.3"/>
                    <measurement group_id="B3" value="5.06" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diaphragmatic Hernia present</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Subjects with Diaphragmatic Hernia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects without Diaphragmatic Hernia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diaphragmatic Hernia length</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" spread="2.3"/>
                    <measurement group_id="B2" value="3.0" spread="1.7"/>
                    <measurement group_id="B3" value="3.3" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number undergoing Endoscopic Mucosal Resection</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Subjects undergoing resection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects not undergoing resection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Inflammation Biomarker Tissue PGE2 Level</title>
        <description>Change from baseline in esophageal tissue biopsy prostaglandin E2 (PGE2) level, as determined by enzyme immunoassay</description>
        <time_frame>3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole</title>
            <description>Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
dexlansoprazole: Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole</title>
            <description>Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
Omeprazole: Escalating doses of omeprazole (20-60 mg/day) for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammation Biomarker Tissue PGE2 Level</title>
          <description>Change from baseline in esophageal tissue biopsy prostaglandin E2 (PGE2) level, as determined by enzyme immunoassay</description>
          <units>nanograms/gram of tissue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="3.16"/>
                    <measurement group_id="O2" value="-0.02" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="3.58"/>
                    <measurement group_id="O2" value="-0.06" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between the two treatment groups at 3 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between the two treatment groups at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Esophageal Inflammation Biomarker COX-2 Gene Expression</title>
        <description>Change from baseline in esophageal issue biopsy cyclooxygenase-2 (COX-2) gene expression, as determined by Western blot.</description>
        <time_frame>3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole</title>
            <description>Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
dexlansoprazole: Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole</title>
            <description>Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
Omeprazole: Escalating doses of omeprazole (20-60 mg/day) for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Esophageal Inflammation Biomarker COX-2 Gene Expression</title>
          <description>Change from baseline in esophageal issue biopsy cyclooxygenase-2 (COX-2) gene expression, as determined by Western blot.</description>
          <units>% of tubulin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.81" spread="73.55"/>
                    <measurement group_id="O2" value="27.17" spread="176.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.54" spread="98.77"/>
                    <measurement group_id="O2" value="25.49" spread="210.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between the two treatment groups at 3 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison between the two treatment groups at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dexlansoprazole</title>
          <description>Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
dexlansoprazole: Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Omeprazole</title>
          <description>Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
Omeprazole: Escalating doses of omeprazole (20-60 mg/day) for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prasad Iyer, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-0970</phone>
      <email>Iyer.Prasad@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

